• 1
    NCCN Practice Guidelines in Oncology-v.2.2006. Available at URL: Accessed on January 18, 2007.
  • 2
    Saltz LB. Understanding and managing chemotherapy-induced diarrhea. J Supp Oncol. 2003; 1: 3546.
  • 3
    O'Brien BE,Kaklamani VG,Benson AB3rd. The assessment and management of cancer treatment-related diarrhea. Clin Colorectal Cancer. 2005; 4: 375381.
  • 4
    Smith RE,Colangelo L,Wieand S, et al. The occurrence of severe enteropathy among patients with stage II/III resected colon cancer (CC) treated with 5-fluorouracil/leucovorin (FL) plus oxaliplatin (FLOX) [abstract]. Proc Am Soc Clin Oncol. 2003: 22. Abstract 1181.
  • 5
    Takaoka E,Kawal K,Ando S, et al. Neutropenic colitis during standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer. Jpn J Clin Oncol. 2006; 36: 6063.
  • 6
    Wenzel C,Urbauer E,Schwarz C, et al. Severe enteropathy associated with ralitrexed and oxaliplatin chemotherapy: report of two patients experiencing this rare, potentially lethal gastrointestinal adverse event. Anticancer Drugs. 2006; 17: 865868.
  • 7
    Avigan D,Richardson P,Elias A, et al. Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors: a case series of a review of the literature. Cancer. 1998; 83: 409414.
  • 8
    Tham RT,Vlasveld LT,Willemze R. Gastrointestinal complications of cytosine-arabinoside chemotherapy: findings on plain abdominal radiographs. AJR Am J Roentgenol. 1990; 154: 9598.
  • 9
    Zamani R,Heldmann M. Enteritis as a complication of adjuvant combination chemotherapy using 5-fluorouracil and leukovorin: clinical and helical computed tomographic features. J La State Med Soc. 2004; 156: 143144.
  • 10
    Kelvin FM,Gramm HF,Gluck WL, et al. Radiologic manifestations of small bowel toxicity due to floxuridine therapy. AJR Am J Roentgenol. 1986; 146: 3943.
  • 11
    Hiehle JFJr,Levine MS. Gastrointestinal toxicity of 5-FU and 5-FUDR: radiographic findings. Can Assoc Radiol J. 1991; 42: 109112.
  • 12
    Fata F,Ron IG,Kemeny N, et al. 5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. Cancer. 1999; 86: 11291134.
  • 13
    Dranitsaris G,Maroun J,Shah A. Estimating the cost of illness in colorectal cancer patients who were hospitalized for severe chemotherapy-induced diarrhea. Can J Gastroenterol. 2005; 19: 8387.
  • 14
    Petrelli N,Herrera L,Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol. 1987; 5: 15591565.
  • 15
    Chou CK. CT manifestations of bowel ischemia. AJR Am J Roentgenol. 2002; 178: 8791.
  • 16
    Sloan JA,Goldberg RM,Sargent DJ, et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol. 2002; 20: 14911498.
  • 17
    Chansky K,Benedetti J,Macdonald JS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer. 2005; 103: 11651171.
  • 18
    Kuebler P,Wieand HS,O'Connell MJ, et al. Oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer. Results from NSABP protocol C-07. J Clin Oncol. 2007; 25: 21982204.
  • 19
    Andre T,Boni C,Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350: 23432351.
  • 20
    Rosenoff S. Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies. Support Care Cancer. 2004; 12: 561570.